Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

S. Tam, Constantine; Trotman, Judith; Opat, Stephen; A. Burger, Jan; Cull, Gavin; Gottlieb, David; Harrup, Rosemary; B. Johnston, Patrick; Marlton, Paula; Muñoz, Javier; F. Seymour, John; Simpson, David; Tedeschi, Alessandra; Elstrom, Rebecca; Yu, Yiling; Tang, Zhiyu; Han, Lynn; Huang, Jane; Novotny, William; Wang, Lai; W. Roberts, Andrew

doi:10.1182/blood.2019001160

Public

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Published in Blood • Jul 24, 2019

Authors:

Constantine S. Tam

Judith Trotman

Stephen Opat

Abstract

Abstract Zanubrutinib is a potent and highly selective inhibitor of Bruton tyrosine kinase (BTK). In this first-in-human, open-label, multicenter, phase 1 study, patients in part 1 (3 + 3 dose escalation) had relapsed/refractory B-cell malignancies and received zanubrutinib 40, 80, 160, or 320 mg on...

Subject

Neutropenia

Medicine

Chronic lymphocytic leukemia

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!